Cancer clinical trials in the region Grand Est
287 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
17 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT07222566
#2025-523461-17-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
5 recruiting sites
Pfizer
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06465953
#2023-510155-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required IPSS-M prognostic scores
Low
Moderately low
Moderately high
High
Very high
Excluded previous treatments
Chemotherapy
Allogeneic stem cell transplant
6 recruiting sites
Servier
Phase 3
Breast cancer
#NCT05512364
#2022-501453-36-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Surgery
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Breast cancer
#NCT07062965
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
Excluded previous treatments at localized stage
Chemotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
Antibody Drug Conjugates (ADC)
13 recruiting sites
Pfizer
Phase 3
Colon cancer
Rectal cancer
#NCT06997497
#2024-517232-22-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05198960
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera
Essential thrombocythemia
Primary myelofibrosis
Required genetic anomalies
JAK2
19 recruiting sites
Hôpital Universitaire de Brest
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06479135
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Targeted therapy
14 recruiting sites
Kartos Therapeutics
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06093672
#2022-502276-23-00
Phase de traitement principale
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera
Required genetic anomalies
JAK2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Targeted therapy
Cytoreductive therapy
9 recruiting sites
Italfarmaco
Phase 3
Breast cancer
#NCT06841354
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Merck Sharp & Dohme LLC